Venus Remedies Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 3, 2025, 10:29 pm

Competitors of Venus Remedies Ltd

All Competitor Stocks of Venus Remedies Ltd

Quarterly Result

Last Updated: August 20, 2025, 1:30 am

Below is a detailed analysis of the quarterly data for Venus Remedies Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 131.90 Cr.. The value appears to be declining and may need further review. It has decreased from 194.97 Cr. (Mar 2025) to 131.90 Cr., marking a decrease of 63.07 Cr..
• For Expenses, as of Jun 2025, the value is 121.80 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 165.97 Cr. (Mar 2025) to 121.80 Cr., marking a decrease of 44.17 Cr..
• For Operating Profit, as of Jun 2025, the value is 10.10 Cr.. The value appears to be declining and may need further review. It has decreased from 29.00 Cr. (Mar 2025) to 10.10 Cr., marking a decrease of 18.90 Cr..
• For OPM %, as of Jun 2025, the value is 7.66%. The value appears to be declining and may need further review. It has decreased from 14.87% (Mar 2025) to 7.66%, marking a decrease of 7.21%.
• For Other Income, as of Jun 2025, the value is 8.69 Cr.. The value appears strong and on an upward trend. It has increased from 6.76 Cr. (Mar 2025) to 8.69 Cr., marking an increase of 1.93 Cr..
• For Interest, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
• For Depreciation, as of Jun 2025, the value is 6.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.71 Cr. (Mar 2025) to 6.18 Cr., marking an increase of 1.47 Cr..
• For Profit before tax, as of Jun 2025, the value is 12.60 Cr.. The value appears to be declining and may need further review. It has decreased from 31.04 Cr. (Mar 2025) to 12.60 Cr., marking a decrease of 18.44 Cr..
• For Tax %, as of Jun 2025, the value is 23.81%. The value appears to be improving (decreasing) as expected. It has decreased from 32.35% (Mar 2025) to 23.81%, marking a decrease of 8.54%.
• For Net Profit, as of Jun 2025, the value is 9.60 Cr.. The value appears to be declining and may need further review. It has decreased from 21.00 Cr. (Mar 2025) to 9.60 Cr., marking a decrease of 11.40 Cr..
• For EPS in Rs, as of Jun 2025, the value is 7.18. The value appears to be declining and may need further review. It has decreased from 15.71 (Mar 2025) to 7.18, marking a decrease of 8.53.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:11 am

Growth

Last Updated: September 5, 2025, 1:51 pm

Balance Sheet

Last Updated: July 25, 2025, 2:06 pm

Below is a detailed analysis of the balance sheet data for Venus Remedies Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 13.00 Cr..
• For Reserves, as of Mar 2025, the value is 548.00 Cr.. The value appears strong and on an upward trend. It has increased from 474.00 Cr. (Mar 2024) to 548.00 Cr., marking an increase of 74.00 Cr..
• For Borrowings, as of Mar 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 41.00 Cr. (Mar 2024) to 2.00 Cr., marking a decrease of 39.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 153.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 98.00 Cr. (Mar 2024) to 153.00 Cr., marking an increase of 55.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 716.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 627.00 Cr. (Mar 2024) to 716.00 Cr., marking an increase of 89.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 229.00 Cr.. The value appears strong and on an upward trend. It has increased from 219.00 Cr. (Mar 2024) to 229.00 Cr., marking an increase of 10.00 Cr..
• For CWIP, as of Mar 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 21.00 Cr. (Mar 2024) to 26.00 Cr., marking an increase of 5.00 Cr..
• For Investments, as of Mar 2025, the value is 84.00 Cr.. The value appears strong and on an upward trend. It has increased from 19.00 Cr. (Mar 2024) to 84.00 Cr., marking an increase of 65.00 Cr..
• For Other Assets, as of Mar 2025, the value is 376.00 Cr.. The value appears strong and on an upward trend. It has increased from 368.00 Cr. (Mar 2024) to 376.00 Cr., marking an increase of 8.00 Cr..
• For Total Assets, as of Mar 2025, the value is 716.00 Cr.. The value appears strong and on an upward trend. It has increased from 627.00 Cr. (Mar 2024) to 716.00 Cr., marking an increase of 89.00 Cr..

Notably, the Reserves (548.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Venus Remedies Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 33.90. This value is within the healthy range. It has increased from 21.31 (Mar 24) to 33.90, marking an increase of 12.59.
• For Diluted EPS (Rs.), as of Mar 25, the value is 33.90. This value is within the healthy range. It has increased from 21.31 (Mar 24) to 33.90, marking an increase of 12.59.
• For Cash EPS (Rs.), as of Mar 25, the value is 50.74. This value is within the healthy range. It has increased from 41.10 (Mar 24) to 50.74, marking an increase of 9.64.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 419.65. It has increased from 364.74 (Mar 24) to 419.65, marking an increase of 54.91.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 419.65. It has increased from 364.74 (Mar 24) to 419.65, marking an increase of 54.91.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 484.69. It has increased from 449.95 (Mar 24) to 484.69, marking an increase of 34.74.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 63.20. This value is within the healthy range. It has increased from 53.25 (Mar 24) to 63.20, marking an increase of 9.95.
• For PBIT / Share (Rs.), as of Mar 25, the value is 46.37. This value is within the healthy range. It has increased from 33.47 (Mar 24) to 46.37, marking an increase of 12.90.
• For PBT / Share (Rs.), as of Mar 25, the value is 53.73. This value is within the healthy range. It has increased from 33.40 (Mar 24) to 53.73, marking an increase of 20.33.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 33.90. This value is within the healthy range. It has increased from 21.31 (Mar 24) to 33.90, marking an increase of 12.59.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 33.90. This value is within the healthy range. It has increased from 21.31 (Mar 24) to 33.90, marking an increase of 12.59.
• For PBDIT Margin (%), as of Mar 25, the value is 13.04. This value is within the healthy range. It has increased from 11.83 (Mar 24) to 13.04, marking an increase of 1.21.
• For PBIT Margin (%), as of Mar 25, the value is 9.56. This value is below the healthy minimum of 10. It has increased from 7.43 (Mar 24) to 9.56, marking an increase of 2.13.
• For PBT Margin (%), as of Mar 25, the value is 11.08. This value is within the healthy range. It has increased from 7.42 (Mar 24) to 11.08, marking an increase of 3.66.
• For Net Profit Margin (%), as of Mar 25, the value is 6.99. This value is within the healthy range. It has increased from 4.73 (Mar 24) to 6.99, marking an increase of 2.26.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.99. This value is below the healthy minimum of 8. It has increased from 4.73 (Mar 24) to 6.99, marking an increase of 2.26.
• For Return on Networth / Equity (%), as of Mar 25, the value is 8.07. This value is below the healthy minimum of 15. It has increased from 5.84 (Mar 24) to 8.07, marking an increase of 2.23.
• For Return on Capital Employeed (%), as of Mar 25, the value is 10.69. This value is within the healthy range. It has increased from 8.17 (Mar 24) to 10.69, marking an increase of 2.52.
• For Return On Assets (%), as of Mar 25, the value is 6.33. This value is within the healthy range. It has increased from 4.54 (Mar 24) to 6.33, marking an increase of 1.79.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.07 (Mar 24) to 0.00, marking a decrease of 0.07.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.08 (Mar 24) to 0.00, marking a decrease of 0.08.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.96. It has decreased from 0.97 (Mar 24) to 0.96, marking a decrease of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 3.31. This value exceeds the healthy maximum of 3. It has decreased from 4.53 (Mar 24) to 3.31, marking a decrease of 1.22.
• For Quick Ratio (X), as of Mar 25, the value is 2.58. This value exceeds the healthy maximum of 2. It has decreased from 2.99 (Mar 24) to 2.58, marking a decrease of 0.41.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.83. This value is within the healthy range. It has increased from 2.85 (Mar 24) to 5.83, marking an increase of 2.98.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 1,291.82. This value is within the healthy range. It has increased from 759.66 (Mar 24) to 1,291.82, marking an increase of 532.16.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 542.31. This value is within the healthy range. It has increased from 305.06 (Mar 24) to 542.31, marking an increase of 237.25.
• For Enterprise Value (Cr.), as of Mar 25, the value is 322.06. It has decreased from 409.53 (Mar 24) to 322.06, marking a decrease of 87.47.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.49. This value is below the healthy minimum of 1. It has decreased from 0.68 (Mar 24) to 0.49, marking a decrease of 0.19.
• For EV / EBITDA (X), as of Mar 25, the value is 3.81. This value is below the healthy minimum of 5. It has decreased from 5.75 (Mar 24) to 3.81, marking a decrease of 1.94.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.72 (Mar 24) to 0.61, marking a decrease of 0.11.
• For Price / BV (X), as of Mar 25, the value is 0.71. This value is below the healthy minimum of 1. It has decreased from 0.89 (Mar 24) to 0.71, marking a decrease of 0.18.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.72 (Mar 24) to 0.61, marking a decrease of 0.11.
• For EarningsYield, as of Mar 25, the value is 0.11. This value is below the healthy minimum of 5. It has increased from 0.06 (Mar 24) to 0.11, marking an increase of 0.05.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness